Hsp110 over-expression increases the immunogenicity of the murine CT26 colon tumor

Xiang Yang Wang, Ying Li, Masoud H. Manjili, Elizabeth A. Repasky, Andrew Mark Pardoll, John R. Subjeck

Research output: Contribution to journalArticle

Abstract

Several studies have suggested a positive correlation between heat shock protein (hsp) expression and tumor immunogenicity. Independently, many studies have shown that hsp purified from tumors can be used as a tumor-specific vaccine. In this study, we have explored the connection between hsp expression and anti-tumor immunity by transducing murine CT26 colon carcinoma cells with the cDNA of a major hsp, i.e. hsp110. We have shown that over-expression of hsp110 has no effect on CT26 tumor cell growth in vitro, and does not inhibit their anchorage-independent growth capacity. However, in situ, hsp110 over-expressing CT26 tumor (CT26-hsp110) grew at a significantly reduced rate as compared to the wild-type CT26 tumor in immunocompetent mice. Moreover, immunization of mice with inactivated CT26-hsp110 cells significantly inhibited the growth of wild-type CT26 tumor. This immunity was associated with an increased frequency of tumor-specific T cells after vaccination. An in vivo antibody depletion assay demonstrated that inactivated CT26-hsp110 cells elicited anti-tumor responses involving CD8+ T cells and natural killer (NK) cells, but not CD4+ T cells. Lastly, the effect of the addition of granulocyte-macrophage colony stimulating factor (GM-CSF) to these vaccine formulations was determined. Mice immunized with irradiated CT26-hsp110 cells combined with GM-CSF-producing bystander cells revealed a complete inhibition of CT26 tumor growth, indicating a synergy between inactivated CT26-hsp110 vaccine activity and GM-CSF. These observations demonstrate that manipulation of hsp110 expression in tumors, specifically when combined with GM-CSF, represents a potentially powerful approach to cancer vaccine formulation.

Original languageEnglish (US)
Pages (from-to)311-319
Number of pages9
JournalCancer Immunology Immunotherapy
Volume51
Issue number6
DOIs
StatePublished - 2002

Fingerprint

Colon
Neoplasms
Granulocyte-Macrophage Colony-Stimulating Factor
Heat-Shock Proteins
Cancer Vaccines
Growth
T-Lymphocytes
HSP110 Heat-Shock Proteins
Immunity
Vaccines
Natural Killer Cells
Immunization
Vaccination
Complementary DNA
Carcinoma
Antibodies

Keywords

  • Gene therapy
  • GM-CSF
  • Heat shock protein
  • Tumor Immunogenicity
  • Vaccine

ASJC Scopus subject areas

  • Cancer Research
  • Immunology
  • Oncology

Cite this

Hsp110 over-expression increases the immunogenicity of the murine CT26 colon tumor. / Wang, Xiang Yang; Li, Ying; Manjili, Masoud H.; Repasky, Elizabeth A.; Pardoll, Andrew Mark; Subjeck, John R.

In: Cancer Immunology Immunotherapy, Vol. 51, No. 6, 2002, p. 311-319.

Research output: Contribution to journalArticle

Wang, Xiang Yang ; Li, Ying ; Manjili, Masoud H. ; Repasky, Elizabeth A. ; Pardoll, Andrew Mark ; Subjeck, John R. / Hsp110 over-expression increases the immunogenicity of the murine CT26 colon tumor. In: Cancer Immunology Immunotherapy. 2002 ; Vol. 51, No. 6. pp. 311-319.
@article{886d63c6f2dc42e68cb6ae08d8e34064,
title = "Hsp110 over-expression increases the immunogenicity of the murine CT26 colon tumor",
abstract = "Several studies have suggested a positive correlation between heat shock protein (hsp) expression and tumor immunogenicity. Independently, many studies have shown that hsp purified from tumors can be used as a tumor-specific vaccine. In this study, we have explored the connection between hsp expression and anti-tumor immunity by transducing murine CT26 colon carcinoma cells with the cDNA of a major hsp, i.e. hsp110. We have shown that over-expression of hsp110 has no effect on CT26 tumor cell growth in vitro, and does not inhibit their anchorage-independent growth capacity. However, in situ, hsp110 over-expressing CT26 tumor (CT26-hsp110) grew at a significantly reduced rate as compared to the wild-type CT26 tumor in immunocompetent mice. Moreover, immunization of mice with inactivated CT26-hsp110 cells significantly inhibited the growth of wild-type CT26 tumor. This immunity was associated with an increased frequency of tumor-specific T cells after vaccination. An in vivo antibody depletion assay demonstrated that inactivated CT26-hsp110 cells elicited anti-tumor responses involving CD8+ T cells and natural killer (NK) cells, but not CD4+ T cells. Lastly, the effect of the addition of granulocyte-macrophage colony stimulating factor (GM-CSF) to these vaccine formulations was determined. Mice immunized with irradiated CT26-hsp110 cells combined with GM-CSF-producing bystander cells revealed a complete inhibition of CT26 tumor growth, indicating a synergy between inactivated CT26-hsp110 vaccine activity and GM-CSF. These observations demonstrate that manipulation of hsp110 expression in tumors, specifically when combined with GM-CSF, represents a potentially powerful approach to cancer vaccine formulation.",
keywords = "Gene therapy, GM-CSF, Heat shock protein, Tumor Immunogenicity, Vaccine",
author = "Wang, {Xiang Yang} and Ying Li and Manjili, {Masoud H.} and Repasky, {Elizabeth A.} and Pardoll, {Andrew Mark} and Subjeck, {John R.}",
year = "2002",
doi = "10.1007/s00262-002-0287-1",
language = "English (US)",
volume = "51",
pages = "311--319",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "6",

}

TY - JOUR

T1 - Hsp110 over-expression increases the immunogenicity of the murine CT26 colon tumor

AU - Wang, Xiang Yang

AU - Li, Ying

AU - Manjili, Masoud H.

AU - Repasky, Elizabeth A.

AU - Pardoll, Andrew Mark

AU - Subjeck, John R.

PY - 2002

Y1 - 2002

N2 - Several studies have suggested a positive correlation between heat shock protein (hsp) expression and tumor immunogenicity. Independently, many studies have shown that hsp purified from tumors can be used as a tumor-specific vaccine. In this study, we have explored the connection between hsp expression and anti-tumor immunity by transducing murine CT26 colon carcinoma cells with the cDNA of a major hsp, i.e. hsp110. We have shown that over-expression of hsp110 has no effect on CT26 tumor cell growth in vitro, and does not inhibit their anchorage-independent growth capacity. However, in situ, hsp110 over-expressing CT26 tumor (CT26-hsp110) grew at a significantly reduced rate as compared to the wild-type CT26 tumor in immunocompetent mice. Moreover, immunization of mice with inactivated CT26-hsp110 cells significantly inhibited the growth of wild-type CT26 tumor. This immunity was associated with an increased frequency of tumor-specific T cells after vaccination. An in vivo antibody depletion assay demonstrated that inactivated CT26-hsp110 cells elicited anti-tumor responses involving CD8+ T cells and natural killer (NK) cells, but not CD4+ T cells. Lastly, the effect of the addition of granulocyte-macrophage colony stimulating factor (GM-CSF) to these vaccine formulations was determined. Mice immunized with irradiated CT26-hsp110 cells combined with GM-CSF-producing bystander cells revealed a complete inhibition of CT26 tumor growth, indicating a synergy between inactivated CT26-hsp110 vaccine activity and GM-CSF. These observations demonstrate that manipulation of hsp110 expression in tumors, specifically when combined with GM-CSF, represents a potentially powerful approach to cancer vaccine formulation.

AB - Several studies have suggested a positive correlation between heat shock protein (hsp) expression and tumor immunogenicity. Independently, many studies have shown that hsp purified from tumors can be used as a tumor-specific vaccine. In this study, we have explored the connection between hsp expression and anti-tumor immunity by transducing murine CT26 colon carcinoma cells with the cDNA of a major hsp, i.e. hsp110. We have shown that over-expression of hsp110 has no effect on CT26 tumor cell growth in vitro, and does not inhibit their anchorage-independent growth capacity. However, in situ, hsp110 over-expressing CT26 tumor (CT26-hsp110) grew at a significantly reduced rate as compared to the wild-type CT26 tumor in immunocompetent mice. Moreover, immunization of mice with inactivated CT26-hsp110 cells significantly inhibited the growth of wild-type CT26 tumor. This immunity was associated with an increased frequency of tumor-specific T cells after vaccination. An in vivo antibody depletion assay demonstrated that inactivated CT26-hsp110 cells elicited anti-tumor responses involving CD8+ T cells and natural killer (NK) cells, but not CD4+ T cells. Lastly, the effect of the addition of granulocyte-macrophage colony stimulating factor (GM-CSF) to these vaccine formulations was determined. Mice immunized with irradiated CT26-hsp110 cells combined with GM-CSF-producing bystander cells revealed a complete inhibition of CT26 tumor growth, indicating a synergy between inactivated CT26-hsp110 vaccine activity and GM-CSF. These observations demonstrate that manipulation of hsp110 expression in tumors, specifically when combined with GM-CSF, represents a potentially powerful approach to cancer vaccine formulation.

KW - Gene therapy

KW - GM-CSF

KW - Heat shock protein

KW - Tumor Immunogenicity

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=0036308936&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036308936&partnerID=8YFLogxK

U2 - 10.1007/s00262-002-0287-1

DO - 10.1007/s00262-002-0287-1

M3 - Article

C2 - 12111119

AN - SCOPUS:0036308936

VL - 51

SP - 311

EP - 319

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 6

ER -